About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Western Reaction to Changes in Chinese Patent Law | Main | Obama Acts to Limit New Federal Rules »

January 20, 2009

Comments

It's funny that in one section Grossman says that patent reform should not favor one industry over another and everywhere else his reforms favor drug companies over high tech.

In a case of the pot calling the kettle black, Mr. Grossman can claim that "[s]pecial interests are angling for advantage within America's patent system," yet ignores the obvious special interest angle of BIO in advocating for extensive biologics data exclusivity. Perhaps he distinguishes himself from his own admonition by advocating regulatory reform rather than patent reform?

The comments to this entry are closed.

July 2020

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31